Axon Enterprise (NASDAQ:AXON) Given New $500.00 Price Target at Needham & Company LLC

Axon Enterprise (NASDAQ:AXON) had its price target reduced by Needham & Company LLC from $750.00 to $500.00 in a research report report published on Friday morning, MarketBeat.com reports. They currently have a buy rating on the biotechnology company’s stock.

Other equities research analysts have also recently issued research reports about the stock. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Axon Enterprise in a report on Tuesday, July 21st. Weiss Ratings reissued a “hold (c-)” rating on shares of Axon Enterprise in a research report on Tuesday. Argus boosted their target price on Axon Enterprise from $460.00 to $600.00 and gave the company a “buy” rating in a research note on Thursday, September 3rd. Raymond James Financial set a $675.00 price target on Axon Enterprise in a research report on Thursday, October 15th. Finally, Piper Sandler dropped their price target on Axon Enterprise from $732.00 to $561.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 20th. Thirteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $631.35.

Axon Enterprise Stock Performance

Shares of NASDAQ:AXON traded down $69.56 during midday trading on Friday, reaching $313.00. The company had a trading volume of 5,224,684 shares, compared to its average volume of 975,165. The stock has a market cap of $25.43 billion, a P/E ratio of 100.32, a P/E/G ratio of 8.09 and a beta of 1.48. The company’s 50 day moving average price is $441.53 and its 200 day moving average price is $475.20. The company has a current ratio of 2.15, a quick ratio of 1.80 and a debt-to-equity ratio of 0.47. Axon Enterprise has a 52-week low of $307.00 and a 52-week high of $665.07.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.89 by ($0.17). The company had revenue of $908.55 million for the quarter, compared to analysts’ expectations of $934.33 million. Axon Enterprise had a return on equity of 2.84% and a net margin of 6.19%. The business’s quarterly revenue was up 27.8% on a year-over-year basis. During the same quarter last year, the business posted $1.17 EPS. As a group, sell-side analysts anticipate that Axon Enterprise will post 2.10 EPS for the current fiscal year.

Insider Activity

In related news, insider Jeffrey Kunins sold 9,605 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $626.70, for a total transaction of $6,019,453.50. Following the completion of the transaction, the insider owned 97,761 shares of the company’s stock, valued at approximately $61,266,818.70. The trade was a 8.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Patrick Smith sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $508.99, for a total transaction of $5,089,900.00. Following the sale, the chief executive officer directly owned 3,118,012 shares in the company, valued at $1,587,036,927.88. This trade represents a 0.32% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 37,397 shares of company stock valued at $21,234,034 over the last ninety days. 4.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. State Street Corp grew its position in Axon Enterprise by 5,700.2% during the second quarter. State Street Corp now owns 213,561,844 shares of the biotechnology company’s stock worth $119,724,905,000 after buying an additional 209,879,882 shares in the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of Axon Enterprise by 18,050.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 13,200,075 shares of the biotechnology company’s stock valued at $7,400,094,000 after acquiring an additional 13,127,348 shares in the last quarter. Robeco Institutional Asset Management B.V. raised its holdings in shares of Axon Enterprise by 391,214.9% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 6,988,884 shares of the biotechnology company’s stock valued at $2,952,943,000 after acquiring an additional 6,987,098 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in shares of Axon Enterprise by 5,022.8% during the 3rd quarter. Assenagon Asset Management S.A. now owns 4,266,589 shares of the biotechnology company’s stock valued at $1,802,719,000 after acquiring an additional 4,183,302 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Axon Enterprise by 8,432.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,537,957 shares of the biotechnology company’s stock valued at $1,983,414,000 after acquiring an additional 3,496,493 shares during the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q3 revenue reached a record $909 million, up 28% year over year, while software and services revenue rose 43%. Axon also reported AI annual recurring revenue above $100 million, signaling continued demand for its software and AI offerings. Axon Q3 results
• Neutral Sentiment: Axon committed an additional $1.2 billion to drone maker Skydio, bringing its stake to 37% and making it Skydio’s exclusive public-safety distributor in the U.S. and Canada. The move could expand Axon’s Drone as First Responder business, but its scale also raises investment and execution risks. Reuters: Axon invests in Skydio
• Negative Sentiment: Q3 adjusted earnings of $1.72 per share and revenue of $908.55 million fell short of analyst expectations. Axon’s 2026 revenue forecast was reduced to $3.6 billion from a consensus of about $3.7 billion; its Q4 revenue guidance also came in below estimates. The company cited delays in federal counter-drone projects, while margin pressure added to concerns. Zacks: Q3 miss and outlook
• Negative Sentiment: Several analysts lowered price targets after the results, and Craig Hallum downgraded AXON from Buy to Hold, adding to pressure on investor sentiment. Benzinga: analyst forecast changes
• Negative Sentiment: A class-action lawsuit over Axon’s license-plate surveillance practices is a potential additional legal and reputational overhang. Class-action announcement

Axon Enterprise Company Profile

Axon Enterprise develops technology and services for public safety agencies. Its products include TASER conducted-energy weapons, body-worn and in-car cameras, and related hardware designed to support law enforcement and other safety professionals.

The company also provides cloud-based software for managing digital evidence, records and operational workflows. Its Axon Evidence platform helps agencies store, organize and share video and other evidence, while its broader software offerings include tools for dispatch and records management.

Founded in 1993 as TASER International, the company adopted the name Axon Enterprise in 2017 as it expanded beyond conducted-energy weapons into connected devices and software.